NCT06354998

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

Randomized, Observer-Blind, Active-Controlled, Clinical Trial to Assess the Immunogenicity of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 217 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Conditions

• SARS-CoV-2

Interventions

Type	Name	Description
BIOLOGICAL	Investigational mRNA-1273.815	Sterile solution for injection
BIOLOGICAL	Licensed Spikevax Vaccine	Commercially available formulation

Timeline

• Start date: 2024-04-08
• Primary completion: 2024-05-10
• Completion: 2024-05-10
• First posted: 2024-04-09
• Last updated: 2025-05-25
• Results posted: 2025-05-25

Locations

7 sites across 1 country: Australia

Regulatory

• FDA-regulated drug study